Wuhan-based iRegene, which aims to become a global leader in universal chemically induced cell therapy, recently announced the closing of its Series B financing, raising several hundred million RMB. The round was co-led by Orinno Capital and CDBT Group, with additional participation from prominent industry investors and Optics Valley Industrial Investment of Wuhan.

CEC Capital acted as the exclusive financial advisor for iRegene in this round.

The company is also nearing the closing of its Series B+ financing, expected to finalize soon, reflecting ongoing strong interest from the capital markets. CEC Capital will continue to serve as the exclusive financial advisor for subsequent funding rounds.

The funds will be used to accelerate the clinical development of the company’s Parkinson’s disease treatment products, NouvNeu001/NouvNeu003, and ophthalmology treatment product, NouvSight001, in both China and the U.S. The financing will also support the advancement of several innovative pipelines, strengthen the company's clinical capabilities, and enhance industrialization efforts.